Home Featured Page 87

Featured

Latest

‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase 3 LSD for MDD Readout

Psychedelic Policy Briefing: Week of June 22nd, 2026

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect

The Psychedelic Practitioner Issue 5: Groups in Practice

Perfect Your Craft and Deliver Your Best Results with Homecoming

PT438 – The Psychedelic Medicine Association and Managing Medical Risk in...

Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt...

BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces...

California Psychedelic Decriminalisation Bill Clears Appropriations Committee with Amendments

PT437 – Exploring Psychedelic Therapies: Iboga, CBD, and Cannabis Paired With...

Natural Medicine Advisory Bulletin #3: August 2023

Psychedelic Bulletin #144: Otsuka to Buy Mindset; Responses to FDA Draft...

FILAMENT HEALTH ENTERS LICENSING AGREEMENT WITH RESET PHARMA

BREAKING: Big Pharma Company Otsuka to Acquire Mindset Pharma for CAD...

EDITOR PICKS

‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase...

Psychedelic Policy Briefing: Week of June 22nd, 2026

Mike Finoia – The Comedy of Conscious Aging, Episode 16

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase 3 LSD for MDD Readout

Psychedelic Policy Briefing: Week of June 22nd, 2026

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect

The Psychedelic Practitioner Issue 5: Groups in Practice

Perfect Your Craft and Deliver Your Best Results with Homecoming

PT438 – The Psychedelic Medicine Association and Managing Medical Risk in...

Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt...

BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces...

California Psychedelic Decriminalisation Bill Clears Appropriations Committee with Amendments

PT437 – Exploring Psychedelic Therapies: Iboga, CBD, and Cannabis Paired With...

Natural Medicine Advisory Bulletin #3: August 2023

Psychedelic Bulletin #144: Otsuka to Buy Mindset; Responses to FDA Draft...

FILAMENT HEALTH ENTERS LICENSING AGREEMENT WITH RESET PHARMA

BREAKING: Big Pharma Company Otsuka to Acquire Mindset Pharma for CAD...

EDITOR PICKS

‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase...

Psychedelic Policy Briefing: Week of June 22nd, 2026

Mike Finoia – The Comedy of Conscious Aging, Episode 16

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY